Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL

Journal of Experimental Medicine

Volumn 189, Issue 8, 1999, Pages 1343-1353

  Griffith, Thomas S ^a   Wiley, Steven R ^a   Kubin, Marek Z ^a   Sedger, Lisa M ^a   Maliszewski, Charles R ^a   Fanger, Neil A ^a  

^a AMGEN INC   (United States)

Author keywords

Apoptosis; Human; Monocyte; TRAIL; Tumor

Indexed keywords

TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; MONOCYTES; PHOSPHATIDYLSERINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033583433     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.8.1343     Document Type: Article

References (58)

1. Adams, D.O., and T.A. Hamilton. 1984. The cell biology of macrophage activation. Annu. Rev. Immunol. 2:283-318.
2. Pfeifer, J.D., M.J. Wick, R.L. Roberts, K. Findlay, S.J. Normark, and C.V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature. 361:359-362.
3. Gosselin, E.J., K. Wardwell, D.R. Gosselin, N. Alter, J.L. Fisher, and P.M. Guyre. 1992. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J. Immunol 149:3477-3481.
4. Ding, A.H., C.F. Nathan, and D.J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:2407-2412.
5. Jewett, A., J.V. Giori, and B. Bonavida. 1990. Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J. Immunol. 145:4065-4071.
6. Steplewski, Z., M.D. Lubeck, and H. Koprowski. 1983. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science. 221: 865-867.
7. te Velde, A.A., and C.G. Figdor. 1992. Monocyte mediated cytotoxic activity against melanoma. Melanoma Res. 1:303-309.
8. Boehm, U., T. Klamp, M. Groot, and J.C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795.
9. Webb, D.S., and T.L. Gerrard. 1990. IFN-alpha and IFN-gamma can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J. Immunol. 144:3643-3648.
10. Weinberg, J.B. 1998. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol. Med. 4:557-591.
11. MacMicking, J., Q.-W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323-350.
12. Zembala, M., M. Siedlar, J. Marcinkiewicz, and J. Pryjma. 1994. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokines and lipopolysaccharide. Eur. J. Immunol. 24:435-439.
13. Weinberg, J.B., M.A. Misukonis, P.J. Shami, S.N. Mason, D.L. Sauls, W.A. Dittman, E.R. Wood, G.K. Smith, B. McDonald, K.E. Bachus, et al. 1995. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood. 86:1184-1195.
14. Konur, A., S.W. Krause, M. Rehli, M. Kreutz, and R. Andreesen. 1996. Human monocytes induce a carcinoma cell line to secrete high amounts of nitric oxide. J. Immunol. 157:2109-2115.
15. Feinman, R., D. Henriksen-DeStefano, M. Tsujimoto, and J. Vilcek. 1987. Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J. Immunol. 138: 635-640.
16. Philip, R., and L.B. Epstein. 1986. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1. Nature. 323:86-89.
17. Solomon, K.A., M.B. Covington, C.P. DeCicco, and R.C. Newton. 1997. The fate of pro-TNF-α following inhibition of metalloprotease-dependent processing to soluble TNF-α in human monocytes. J. Immunol. 159:4524-4531.
18. Fisher, G.H., F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middleton, A.Y. Lin, W. Strober, M.J. Lenardo, and J.M. Puck. 1995. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:935-946.
19. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181:71-77.
20. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
21. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.
22. Katsikis, P.D., E.S. Wunderlich, C.A. Smith, L.A. Herzenberg, and L.A. Herzenberg. 1995. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J. Exp. Med. 181: 2029-2036.
23. + T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor J. Exp. Med. 185:55-64.
24. Galle, P.R., W.J. Hofmann, H. Walczak, H. Schaller, G. Otto, W. Stremmel, P.H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (Apo-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
25. Kiener, P.A., P.M. Davis, B.M. Rankin, S.J. Klebanoff, J.A. Ledbetter, G.C. Starling, and W.C. Liles. 1997. Human monocytic cells contain high levels of intracellular Fas ligand. J. Immunol. 159:1594-1598.
26. + T cells apoptosis. J. Immunol. 158:2456-2463.
27. Wu, M.X., J.F. Daley, R.A. Rasmussen, and S.F. Schlossman. 1995. Monocytes are required to prime peripheral T cells to undergo apoptosis. Proc. Natl. Acad. Sci. USA. 92: 1525-1529.
28. + antigen-specific T cells to undergo apoptosis by HIV-infected monocytes: a two step process involving the gp120 molecule. J. Clin. Invest. 99:257-266.
29. Dockrell, D.H., A.D. Badley, J.S. Villacian, C.J. Heppelmann, A. Algeciras, S. Ziesmer, H. Yagita, D.H. Lynch, P.C. Roche, P.J. Leibson, and C.V. Paya. 1998. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J. Clin. Invest. 101:2394-2405.
30. Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din, C.-P. Huang, J.K. Nicholl, G.R. Sutherland, T. Davis Smith, C. Rauch, C.A. Smith, and R.G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
31. Pan, G., K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V.M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science. 276:111-113.
32. Pan, G., J. Ni, Y.-F. Wei, G.-I. Yu, R. Gentz, and V.M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815-818.
33. Sheridan, J.P., S.A. Marsters, P.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277: 818-821.
34. Walczak, H., M.A. Degli-Esposti, R.S. Johnson, P.J. Smolak, J.Y. Waugh, N. Boiani, M.S. Timour, M.J. Gerhart, K.A. Schooley, C.A. Smith, et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO (Eur. Mol. Biol. Organ.) J. 16:5386-5397.
35. Degli-Esposti, M.A., P.J. Smolak, H. Walczak, J. Waugh, C.-P. Huang, R.F. DuBose, R.G. Goodwin, and C.A. Smith. 1997. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1165-1170.
36. Degli-Esposti, M.A., W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwin. 1997. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813-820.
37. Marsters, S.A., J.P. Sheridan, R.M. Pitti, A. Huang, M. Skubatch, D. Baldwin, J. Yuan, A. Gurney, A.D. Goddard, P. Godowski, and A. Ashkenazi. 1997. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1003-1006.
38. Griffith, T.S., W.A. Chin, G.C. Jackson, D.H. Lynch, and M.Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161: 2833-2840.
39. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
40. Walczak, H., R.E. Miller, B. Gliniak, K. Ariail, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al. 1999. Tumoricidal activity of TRAIL in vivo. Nat. Med. 5:157-163.
41. Pitti, R.M., S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, and A. Ashkenazi. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271:12687-12690.
42. Griffith, T.S., and D.H. Lynch. 1998. TRAIL: a molecule with multiple receptors and control mechanisms. Curr. Opin. Immunol. 10:559-563.
43. Mohler, K.M., P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M. Alderson, S.S. Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, et al. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 370:218-220.
44. Martin, J.H.J., and S.W. Edwards. 1993. Changes in mechanisms of monocyte/macrophage-mediated cytotoxicity during culture. J. Immunol. 150:3478-3486.
45. Fadok, V.A., D.R. Voelker, P.A. Campbell, J.J. Cohen, D.L. Bratton, and P.M. Henson. 1992. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:2207-2216.
46. Martin, S.J., C.P.M. Reutelingsperger, A.J. McGahon, J.A. Rader, R.C.A.A. van Schie, D.M. LaFace, and D.R. Green. 1995. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1545-1556.
47. Adams, D.O. 1989. Molecular interactions in macrophage activation. Immunol. Today. 10:33-35.
48. Nissen-Meyer, J., and T. Espevik. 1987. Effect of antisera against recombinant tumor necrosis factor and the monocyte-derived cytotoxin(s) on monocyte-mediated killing of various tumor cells. Cell. Immunol. 109:384-396.
49. Nissen-Meyer, J., E. Hofsli, T. Espevik, and R. Austgulen. 1988. Involvement of tumor necrosis factor in cytotoxicity mediated by human monocytes. Nat. Immun. Cell Growth Regul. 7:266-279.
50. Keller, R., and R. Keist. 1989. Abilities of activated macrophages to manifest tumoricidal activity and to generate reactive nitrogen intermediates: a comparative study in vitro and ex vivo. Biochem. Biophys. Res. Commun. 164:968-973.
51. Hibbs, J.B., Jr., R.R. Taintor, Z. Vavrin, and E.M. Rachlin. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157:87-94.
52. Pellat, C., Y. Heney, and J.C. Drapier. 1990. IFN-gamma-activated macrophages: detection by electron paramagnetic resonance of complexes between L-arginine-derived nitric oxide and non-heme iron products. Biochem. Biophys. Res. Commun. 166:119-125.
53. Harwix, S., R. Andreesen, E. Ferber, and G. Schwamberger. 1992. Human macrophages secrete a tumoricidal activity distinct from tumour necrosis factor-α and reactive nitrogen intermediates. Res. Immunol. 143:89-94.
54. Sharara, A.I., D.J. Perkins, M.A. Misukonis, S.U. Chan, J.A. Dominitz, and J.B. Weinberg. 1997. Interferon (IFN)-α activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-α in vivo. J. Exp. Med. 186: 1495-1502.
55. Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95: 7556-7561.
56. Zamai, L., M. Ahmad, I.M. Bennett, L. Azzoni, E.S. Alnemri, and B. Perussia. 1998. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 88:2375-2380.
57. Katsikis, P.D., M.E. Garcia-Ojeda, E.S. Wunderlich, C.A. Smith, H. Yagita, K. Okumura, N. Kayagaki, M. Alderson, L.A. Herzenberg, and L.A. Herzenberg. 1996. Activation-induced peripheral blood T cell apoptosis is Fas independent in HIV-infected individuals. Int. Immunol. 8:1311-1317.
58. Katsikis, P.D., M.E. Garcia-Ojeda, J.F. Torres-Roca, I.M. Tijoe, C.A. Smith, L.A. Herzenberg, and L.A. Herzenberg. 1997. Interleukin-1β converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J. Exp. Med. 186:1365-1372.